$XBI $70.13 | -5.04%
Table of Contents:
Covid Updates
$NVAX -2.3% Novavax Submits Variations to Expand Australian and New Zealand Provisional Approval of Nuvaxovid™ COVID-19 Vaccine to Adolescents aged 12 Through 17 Years.
Pipeline Updates
$AFMD -9.5% Affimed Provides Update on ASCO AFM13-104 Oral Presentation.
$MYOV -3.6% Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application (sNDA) for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis.
$EVFM -15.5% Evofem Presents Data Detailing Fewer Urinary Tract Infections in Women Using Phexxi in the Phase 3 AMPOWER Clinical Trial.
$CTXR +6.9% Citius Pharmaceuticals to Accelerate Phase 3 Mino-Lok Trial by Expanding Trial Sites Internationally.
$ANIX +10.6% Anixa Biosciences (ANIX): Partner Cleveland Clinic to present Breast Cancer Vaccine Trial at ASCO.
Want to get weekly catalyst updates?
*We never spam you - unsubscribe anytime*
Business Updates
$SQZ -5.2% SQZ Biotechnologies to Host Live & Virtual R&D Investor Event on May 19, 2022.
$IMGS +1.9% IGM Biosciences Announces Closing of Global Collaboration Agreement with Sanofi.
$JNCE +13.0% Jounce upgraded to Strong Buy at Raymond James after pipeline updates
Posted by DV/FS
Comments